HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB:HSTC), an integrated biotechnology health and wellness company, today announced an initiative launched with EBITDA Capital, LLC in which medical reimbursements would be paid for its treatments.
In view of the recent changes to the federally funded Medicare Programs, through Federal reorganizations and reviews, HST Global, Inc. has launched a new initiative. The Company has requested that EBITDA Capital, LLC and its Political Affiliates initiate a dialogue with the appropriate federal agencies for the purpose of allowing the Company’s treatments for fourth stage cancer to be included in Medicare payment schedules.
Mr. Chet Noblett, Managing General Partner, and his team at EBITDA Capital have initiated a plan of action for contacting the proper government agencies. Mr. Noblett says, “The entire Federal program for medical reimbursement is being reviewed and the cost savings from HST treatments should be considered by the appropriate agencies. Not only does HST offer a credible treatment solution but the savings to taxpayers are extremely important at this time.”
Ron Howell, President and CEO of HST Global, Inc. stated “As I have stated previously, there is a growing population of individuals experiencing the lack of available alternatives in treating late stage cancer. In addition, the costs of these traditional alternatives have sky-rocketed over the past few years. HST is reaching across many opportunities to insure that its treatments and solutions are well recognized as not only affordable but also cost effective.”
About HST Global, Inc.
HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that is developing and or acquiring a network of Wellness Centers worldwide that are primarily focused on the homeopathic and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In this regard, the company primarily focuses on homeopathic and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer.